Parsippany-based Delta Dental of New Jersey announced Thursday it has invested $5 million in the clinical-stage biotechnology company C3 Jian Inc., which is developing a new drug that targets tooth decay.
C3 Jian is focused on the development of drugs that improve oral health care. Its lead product, called C16G2, is a peptide-based antimicrobial drug specifically targeting the bacteria responsible for dental caries, or tooth decay, according to a recent press release.
The company, based in Los Angeles, recently began a phase 2 clinical trial to study the product, which is a mouth rinse, as well as a gel, for dental trays and toothbrush applications.
“Tooth decay is the most common chronic disease of childhood, yet it’s nearly 100 percent preventable,” said Ronald Deblinger, D.M.D., chairman, board of trustees, Delta Dental of New Jersey, in a prepared statement.
“We view this as an investment in exciting research that could potentially stop tooth decay,” added Dennis G. Wilson, president and CEO of Delta Dental.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy